[Irreversible electroporation in pancreatic cancer]

Mengarelli C, Ciapponi A, Alfie V, Lazo E, Bardach A, Garcia Marti S, Pichon Riviere A, Alcaraz A, Augustovski F
Record ID 32018004965
Spanish
Original Title: Electroporación irreversible en cáncer de páncreas
Authors' recommendations: "No evidence comparing the use of irreversible electroporation in resectable pancreatic cancer vs. pancreaticoduodenectomy and/or thermal ablation (radiofrequency and/or cryoablation) has been found. Low-quality evidence obtained from a cohort study shows that irreversible electroporation in unresectable pancreatic cancer plus chemotherapy, versus chemotherapy or chemotherapy plus radiation therapy, may have a considerable net benefit since it increases overall survival in patients under 60 and with less-than-4-cm tumors. The serious adverse events described as related to the procedure include perioperative bleeding and organ lesions. The clinical practice guidelines as well as coverage policies from health funders from high and low-income countries do not mention or cover this technology given the insufficient evidence available; and they consider it is still at experimental stage. In Argentina, it is not included in the Mandatory Medical Plan or cannot be reimbursed by the Unique Reimbursement System. No studies on the cost-effectiveness of this technology have been found for this indication".
Details
Project Status: Completed
Year Published: 2022
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Pancreatic Neoplasms
  • Irreversible Electroporation Therapy
  • Pancreaticoduodenectomy
Contact
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: <p>Institute for Clinical Effectiveness and Health Policy (IECS)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.